A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact

Siri Beier Jensen; Anne Marie Lynge Pedersen; Arjan Vissink; Elo Andersen; CG Brown; AN Davies; J Dutilh; JS Fulton; L Jankovic; NNF Lopes; ALS Mello; LV Muniz; CA Murdoch-Kinch; RG Nair; JJ Napeñas; A Nogueira-Rodrigues; D Saunders; B Stirling; I von Bültzingslöwen; DS Weikel; LS Elting; FKL Spijkervet; M Brennan

doi:10.1007/s00520-010-0837-6

A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact

Siri Beier Jensen, Anne Marie Lynge Pedersen, Arjan Vissink, Elo Andersen, CG Brown, AN Davies, J Dutilh, JS Fulton, L Jankovic, NNF Lopes , ALS Mello , LV Muniz , CA Murdoch-Kinch , RG Nair , JJ Napeñas , A Nogueira-Rodrigues , D Saunders , B Stirling , I von Bültzingslöwen , DS Weikel LS Elting , FKL Spijkervet , M Brennan

Sektion 02

151 Citationer (Scopus)

Abstract

This systematic review aimed to assess the literature for management strategies and economic impact of salivary gland hypofunction and xerostomia induced by cancer therapies and to determine the quality of evidence-based management recommendations. The electronic databases of MEDLINE/PubMed and EMBASE were searched for articles published in English since the 1989 NIH Development Consensus Conference on the Oral Complications of Cancer Therapies until 2008 inclusive. For each article, two independent reviewers extracted information regarding study design, study population, interventions, outcome measures, results, and conclusions. Seventy-two interventional studies met the inclusion criteria. In addition, 49 intensity-modulated radiation therapy (IMRT) studies were included as a management strategy aiming for less salivary gland damage. Management guideline recommendations were drawn up for IMRT, amifostine, muscarinic agonist stimulation, oral mucosal lubricants, acupuncture, and submandibular gland transfer. There is evidence that salivary gland hypofunction and xerostomia induced by cancer therapies can be prevented or symptoms be minimized to some degree, depending on the type of cancer treatment. Management guideline recommendations are provided for IMRT, amifostine, muscarinic agonist stimulation, oral mucosal lubricants, acupuncture, and submandibular gland transfer. Fields of sparse literature identified included effects of gustatory and masticatory stimulation, specific oral mucosal lubricant formulas, submandibular gland transfer, acupuncture, hyperbaric oxygen treatment, management strategies in pediatric cancer populations, and the economic consequences of salivary gland hypofunction and xerostomia

Originalsprog	Engelsk
Tidsskrift	Supportive Care in Cancer
Vol/bind	18
Udgave nummer	8
Sider (fra-til)	1061-1079
Antal sider	19
ISSN	0941-4355
DOI	https://doi.org/10.1007/s00520-010-0837-6
Status	Udgivet - aug. 2010

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1007/s00520-010-0837-6

Citationsformater

Jensen, S. B., Pedersen, A. M. L., Vissink, A., Andersen, E., Brown, CG., Davies, AN., Dutilh, J., Fulton, JS., Jankovic, L., Lopes , NNF., Mello , ALS., Muniz , LV., Murdoch-Kinch , CA., Nair , RG., Napeñas , JJ., Nogueira-Rodrigues , A., Saunders , D., Stirling , B., von Bültzingslöwen , I., ... Brennan, M. (2010). A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact. Supportive Care in Cancer, 18(8), 1061-1079. https://doi.org/10.1007/s00520-010-0837-6

Jensen, SB, Pedersen, AML, Vissink, A, Andersen, E, Brown, CG, Davies, AN, Dutilh, J, Fulton, JS, Jankovic, L, Lopes , NNF, Mello , ALS, Muniz , LV, Murdoch-Kinch , CA, Nair , RG, Napeñas , JJ, Nogueira-Rodrigues , A, Saunders , D, Stirling , B, von Bültzingslöwen , I, Weikel , DS, Elting , LS, Spijkervet , FKL & Brennan, M 2010, 'A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact', Supportive Care in Cancer, bind 18, nr. 8, s. 1061-1079. https://doi.org/10.1007/s00520-010-0837-6

@article{2e36f5d81bb0432fac9a2f4d59f4118c,

title = "A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact",

abstract = "Purpose: This systematic review aimed to assess the literature for management strategies and economic impact of salivary gland hypofunction and xerostomia induced by cancer therapies and to determine the quality of evidence-based management recommendations. Methods: The electronic databases of MEDLINE/PubMed and EMBASE were searched for articles published in English since the 1989 NIH Development Consensus Conference on the Oral Complications of Cancer Therapies until 2008 inclusive. For each article, two independent reviewers extracted information regarding study design, study population, interventions, outcome measures, results, and conclusions. Results: Seventy-two interventional studies met the inclusion criteria. In addition, 49 intensity-modulated radiation therapy (IMRT) studies were included as a management strategy aiming for less salivary gland damage. Management guideline recommendations were drawn up for IMRT, amifostine, muscarinic agonist stimulation, oral mucosal lubricants, acupuncture, and submandibular gland transfer. Conclusions: There is evidence that salivary gland hypofunction and xerostomia induced by cancer therapies can be prevented or symptoms be minimized to some degree, depending on the type of cancer treatment. Management guideline recommendations are provided for IMRT, amifostine, muscarinic agonist stimulation, oral mucosal lubricants, acupuncture, and submandibular gland transfer. Fields of sparse literature identified included effects of gustatory and masticatory stimulation, specific oral mucosal lubricant formulas, submandibular gland transfer, acupuncture, hyperbaric oxygen treatment, management strategies in pediatric cancer populations, and the economic consequences of salivary gland hypofunction and xerostomia.",

author = "Jensen, {Siri Beier} and Pedersen, {Anne Marie Lynge} and Arjan Vissink and Elo Andersen and CG Brown and AN Davies and J Dutilh and JS Fulton and L Jankovic and NNF Lopes and ALS Mello and LV Muniz and CA Murdoch-Kinch and RG Nair and JJ Nape{\~n}as and A Nogueira-Rodrigues and D Saunders and B Stirling and {von B{\"u}ltzingsl{\"o}wen}, I and DS Weikel and LS Elting and FKL Spijkervet and M Brennan",

year = "2010",

month = aug,

doi = "10.1007/s00520-010-0837-6",

language = "English",

volume = "18",

pages = "1061--1079",

journal = "Supportive Care in Cancer",

issn = "0941-4355",

publisher = "Springer",

number = "8",

}

TY - JOUR

T1 - A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact

AU - Jensen, Siri Beier

AU - Pedersen, Anne Marie Lynge

AU - Vissink, Arjan

AU - Andersen, Elo

AU - Brown, CG

AU - Davies, AN

AU - Dutilh, J

AU - Fulton, JS

AU - Jankovic, L

AU - Lopes , NNF

AU - Mello , ALS

AU - Muniz , LV

AU - Murdoch-Kinch , CA

AU - Nair , RG

AU - Napeñas , JJ

AU - Nogueira-Rodrigues , A

AU - Saunders , D

AU - Stirling , B

AU - von Bültzingslöwen , I

AU - Weikel , DS

AU - Elting , LS

AU - Spijkervet , FKL

AU - Brennan, M

PY - 2010/8

Y1 - 2010/8

N2 - Purpose: This systematic review aimed to assess the literature for management strategies and economic impact of salivary gland hypofunction and xerostomia induced by cancer therapies and to determine the quality of evidence-based management recommendations. Methods: The electronic databases of MEDLINE/PubMed and EMBASE were searched for articles published in English since the 1989 NIH Development Consensus Conference on the Oral Complications of Cancer Therapies until 2008 inclusive. For each article, two independent reviewers extracted information regarding study design, study population, interventions, outcome measures, results, and conclusions. Results: Seventy-two interventional studies met the inclusion criteria. In addition, 49 intensity-modulated radiation therapy (IMRT) studies were included as a management strategy aiming for less salivary gland damage. Management guideline recommendations were drawn up for IMRT, amifostine, muscarinic agonist stimulation, oral mucosal lubricants, acupuncture, and submandibular gland transfer. Conclusions: There is evidence that salivary gland hypofunction and xerostomia induced by cancer therapies can be prevented or symptoms be minimized to some degree, depending on the type of cancer treatment. Management guideline recommendations are provided for IMRT, amifostine, muscarinic agonist stimulation, oral mucosal lubricants, acupuncture, and submandibular gland transfer. Fields of sparse literature identified included effects of gustatory and masticatory stimulation, specific oral mucosal lubricant formulas, submandibular gland transfer, acupuncture, hyperbaric oxygen treatment, management strategies in pediatric cancer populations, and the economic consequences of salivary gland hypofunction and xerostomia.

AB - Purpose: This systematic review aimed to assess the literature for management strategies and economic impact of salivary gland hypofunction and xerostomia induced by cancer therapies and to determine the quality of evidence-based management recommendations. Methods: The electronic databases of MEDLINE/PubMed and EMBASE were searched for articles published in English since the 1989 NIH Development Consensus Conference on the Oral Complications of Cancer Therapies until 2008 inclusive. For each article, two independent reviewers extracted information regarding study design, study population, interventions, outcome measures, results, and conclusions. Results: Seventy-two interventional studies met the inclusion criteria. In addition, 49 intensity-modulated radiation therapy (IMRT) studies were included as a management strategy aiming for less salivary gland damage. Management guideline recommendations were drawn up for IMRT, amifostine, muscarinic agonist stimulation, oral mucosal lubricants, acupuncture, and submandibular gland transfer. Conclusions: There is evidence that salivary gland hypofunction and xerostomia induced by cancer therapies can be prevented or symptoms be minimized to some degree, depending on the type of cancer treatment. Management guideline recommendations are provided for IMRT, amifostine, muscarinic agonist stimulation, oral mucosal lubricants, acupuncture, and submandibular gland transfer. Fields of sparse literature identified included effects of gustatory and masticatory stimulation, specific oral mucosal lubricant formulas, submandibular gland transfer, acupuncture, hyperbaric oxygen treatment, management strategies in pediatric cancer populations, and the economic consequences of salivary gland hypofunction and xerostomia.

U2 - 10.1007/s00520-010-0837-6

DO - 10.1007/s00520-010-0837-6

M3 - Journal article

SN - 0941-4355

VL - 18

SP - 1061

EP - 1079

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

IS - 8

ER -

A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater